Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.

@article{Okoduwa2018NephrotoxicityAW,
  title={Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.},
  author={Adeola Okoduwa and Nabeela Ahmed and Yi Guo and Marco R Scipione and John Papadopoulos and Daniel Pereira Eiras and Yanina Dubrovskaya},
  journal={Antimicrobial agents and chemotherapy},
  year={2018},
  volume={62 8}
}
Nephrotoxicity is a known adverse effect of polymyxin B (PMB). Animal data suggest that once-daily dosing may reduce the rate and delay the onset of acute kidney injury (AKI). In a multicenter retrospective study, we evaluated adult patients with a creatinine clearance (CrCl) of ≥30 ml/min who received ≥48 h of PMB therapy. The primary endpoint was the difference in rate of AKI comparing once- and twice-daily PMB dosing. The secondary endpoints included the time to AKI and the recovery of renal… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

A practical guide to propensity score analysis for applied clinical research.

  • Behaviour research and therapy
  • 2017
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.

  • Antimicrobial agents and chemotherapy
  • 2017
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL